By Don Sharpe As usual, the NCCN annual meeting held on March 9 – 13 in Hollywood, Florida, featured a timely and topical expert roundtable, this one titled “Molecular Testing – Implications for Practice and Policy”. The panel discussion featured Scott Gottlieb, MD, American Enterprise Institute; Louis Jacques, MD, Centers for Medicare and Medicaid Services; [...]
Incyte (INCY) and their partner Novartis have reported that ruxolitinib (INC424), has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis (MF), when compared to best available therapy in a second Phase 3 trial. The European study, called COMFORT-II, showed that treatment with ruxolitinib provided a statistically significant reduction in spleen [...]
ORLANDO, FL – The high cost of managing prostate cancer could be substantially reduced if physicians incorporated results from three important studies presented at the 2011 ASCO Genitourinary Cancers Symposium held here on February 17-19, 2011. The take-home messages from these studies are as follows: Intermittent androgen suppression (IAD) is as effective as continuous androgen [...]
OBR green is our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register to begin receiving OBR green today. View the Most Recent Issue»
